A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis - Trial NCT06418529
Access comprehensive clinical trial information for NCT06418529 through Pure Global AI's free database. This phase not specified trial is sponsored by Pfizer and is currently Not yet recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 20000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pfizer
Timeline & Enrollment
N/A
May 15, 2024
Jul 15, 2024
Primary Outcome
Percentage of Participants With Clinical Disease Activity Index (CDAI) =10.0
Summary
The purpose of this study is to learn how different types of medicines may improve disease
 activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes
 pain and swelling.
 
 The study will look at data from a large, US-based group of RA patients who have taken the
 below medicines:
 
 - Tofacitinib
 
 - Abatacept
 
 - Tocilizumab or sarilumab
 
 The study will compare clinical disease activity scores of patients on the different
 medicines taken. The study will also decide whether some patient traits or disease factors
 play a role in how medicines may improve disease activity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06418529
Non-Device Trial